Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, has successfully regained compliance with the Nasdaq's minimum bid price requirement, as confirmed by a formal notice from The Nasdaq Stock Market, LLC on October 9, 2024. The company's common stock had previously failed to maintain the required $1.00 minimum closing bid price over a 30-day period, but has since achieved compliance by maintaining a closing bid price of $1.00 or more for 20 consecutive trading days starting September 11, 2024. Following this achievement, Allarity issued a press release on October 10, 2024, to announce its regained compliance. The company's CEO, Thomas Jensen, expressed satisfaction with the resolution of the compliance issue and emphasized the company's continued focus on advancing its stenoparib program, particularly the Phase 2 trial for advanced ovarian cancer. Stenoparib is a dual-targeted inhibitor of PARP1/2 and Tankyrase 1 and 2, with potential therapeutic benefits in cancer treatment due to its unique action on the Wnt signaling pathway. Allarity holds exclusive global rights for the development and commercialization of stenoparib.

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, has successfully regained compliance with the Nasdaq's minimum bid price requirement, as confirmed by a formal notice from The Nasdaq Stock Market, LLC on October 9, 2024. The company's common stock had previously failed to maintain the required $1.00 minimum closing bid price over a 30-day period, but has since achieved compliance by maintaining a closing bid price of $1.00 or more for 20 consecutive trading days starting September 11, 2024. Following this achievement, Allarity issued a press release on October 10, 2024, to announce its regained compliance. The company's CEO, Thomas Jensen, expressed satisfaction with the resolution of the compliance issue and emphasized the company's continued focus on advancing its stenoparib program, particularly the Phase 2 trial for advanced ovarian cancer. Stenoparib is a dual-targeted inhibitor of PARP1/2 and Tankyrase 1 and 2, with potential therapeutic benefits in cancer treatment due to its unique action on the Wnt signaling pathway. Allarity holds exclusive global rights for the development and commercialization of stenoparib.